Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2006 1
2007 2
2008 5
2009 2
2010 2
2011 2
2012 8
2013 13
2014 7
2015 7
2016 9
2017 13
2018 12
2019 11
2020 14
2021 23
2022 29
2023 22
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

159 results

Results by year

Filters applied: . Clear all
Page 1
Feasibility of local therapy for recurrent pancreatic cancer.
Sato H, Yoshida R, Yasui K, Umeda Y, Yoshida K, Fuji T, Kumano K, Takagi K, Yagi T, Fujiwara T. Sato H, et al. Among authors: umeda y. Pancreatology. 2022 Sep;22(6):774-781. doi: 10.1016/j.pan.2022.05.004. Epub 2022 May 24. Pancreatology. 2022. PMID: 35641368 Review.
Oncolytic virus-mediated p53 overexpression promotes immunogenic cell death and efficacy of PD-1 blockade in pancreatic cancer.
Araki H, Tazawa H, Kanaya N, Kajiwara Y, Yamada M, Hashimoto M, Kikuchi S, Kuroda S, Yoshida R, Umeda Y, Urata Y, Kagawa S, Fujiwara T. Araki H, et al. Among authors: umeda y. Mol Ther Oncolytics. 2022 Sep 13;27:3-13. doi: 10.1016/j.omto.2022.09.003. eCollection 2022 Dec 15. Mol Ther Oncolytics. 2022. PMID: 36212775 Free PMC article.
Dual antiplatelet therapy inhibits neutrophil extracellular traps to reduce liver micrometastases of intrahepatic cholangiocarcinoma.
Yoshimoto M, Kagawa S, Kajioka H, Taniguchi A, Kuroda S, Kikuchi S, Kakiuchi Y, Yagi T, Nogi S, Teraishi F, Shigeyasu K, Yoshida R, Umeda Y, Noma K, Tazawa H, Fujiwara T. Yoshimoto M, et al. Among authors: umeda y. Cancer Lett. 2023 Jul 28;567:216260. doi: 10.1016/j.canlet.2023.216260. Epub 2023 Jun 7. Cancer Lett. 2023. PMID: 37295551
ADAR1 is a promising risk stratification biomarker of remnant liver recurrence after hepatic metastasectomy for colorectal cancer.
Hata N, Shigeyasu K, Umeda Y, Yano S, Takeda S, Yoshida K, Fuji T, Yoshida R, Yasui K, Umeda H, Takahashi T, Kondo Y, Kishimoto H, Mori Y, Teraishi F, Yamamoto H, Michiue H, Nakamura K, Tazawa H, Fujiwara T. Hata N, et al. Among authors: umeda y. Sci Rep. 2023 Feb 6;13(1):2078. doi: 10.1038/s41598-023-29397-z. Sci Rep. 2023. PMID: 36747029 Free PMC article.
RNA Editing is a Valuable Biomarker for Predicting Carcinogenesis in Ulcerative Colitis.
Takahashi K, Shigeyasu K, Kondo Y, Gotoh K, Yano S, Umeda Y, Inokuchi T, Xu C, Yoshida K, Umeda H, Takahashi T, Takeda S, Yoshida R, Teraishi F, Kishimoto H, Mori Y, Noma K, Okugawa Y, Hiraoka S, Michiue H, Tazawa H, Matsushita O, Goel A, Fujiwara T. Takahashi K, et al. Among authors: umeda y. J Crohns Colitis. 2023 May 3;17(5):754-766. doi: 10.1093/ecco-jcc/jjac186. J Crohns Colitis. 2023. PMID: 36528792 Free article.
159 results